# A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT02521870** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dynavax Technologies Corporation** · enrollment: 241 (actual)

## Conditions studied

- Metastatic Melanoma
- Head Neck Cancer

## Interventions

- **DRUG:** SD-101(1)
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** SD-101(2)
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** SD-101(3)
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02521870
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 241 (ACTUAL)
- **Why stopped:** A strategic restructuring including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101.
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521870, "A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02521870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*